Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Clin Ther. 2009 Jun; 31(6):1177-91.